SIGN UP
LOG IN
MARKET
FDMT
FDMT
4D Molecular Therapeutics Inc.
NASDAQ
24.78
-0.52
-2.06%
After Hours: 25.33 +0.55 +2.22% 16:07 04/18 EDT
OPEN
25.04
PREV CLOSE
25.30
HIGH
25.27
LOW
24.71
VOLUME
417.55K
TURNOVER
0
52 WEEK HIGH
36.25
52 WEEK LOW
9.44
MARKET CAP
1.27B
P/E (TTM)
-9.6158
1D
5D
1M
3M
1Y
5Y
4D Molecular Therapeutics Price Target Raised to $40.00/Share From $35.00 by RBC Capital
Dow Jones · 3d ago
4D Molecular Therapeutics Is Maintained at Outperform by RBC Capital
Dow Jones · 3d ago
RBC Capital Maintains Outperform on 4D Molecular Therapeutics, Raises Price Target to $40
Benzinga · 3d ago
4D Molecular Therapeutics new overweight at Barclays on genetic medicine platform
Barclays has started 4D Molecular Therapeutics at overweight. The firm has a $45 price target for the stock. The company's lead asset, 4D-150, is a gene therapy candidate for macular degeneration. Barclays cites the validation of the company's AAV vector technology for delivering gene therapies.
Seeking Alpha · 3d ago
Institutional owners may ignore 4D Molecular Therapeutics, Inc.'s (NASDAQ:FDMT) recent US$83m market cap decline as longer-term profits stay in the green
A total of 7 investors have a majority stake in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) with 52% of the company. Institutional investors own a large portion of the stock, but the company is not owned by all of them. 7 of the top 7 shareholders have a 50% stake in the company with 50% of its shares. The company is owned by institutions and hedge funds. 4D molecular therapeutics has a meaningful stake of US$48m in theCompany. We look at the ownership groups of 4d moleculartherapeutics and other companies.
Simply Wall St · 3d ago
4D Molecular Therapeutics Price Target Announced at $45.00/Share by Barclays
Dow Jones · 3d ago
4D Molecular Therapeutics Initiated at Overweight by Barclays
Dow Jones · 3d ago
Barclays Initiates Coverage On 4D Molecular Therapeutics with Overweight Rating, Announces Price Target of $45
Benzinga · 3d ago
About FDMT
4D Molecular Therapeutics, Inc. is a clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat diseases in ophthalmology and pulmonology. The Company has a portfolio of genetic medicine product candidates, with five product candidates in clinical trials in seven patient populations: 4D-150 for the treatment of wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), 4D-710 for the treatment of cystic fibrosis lung disease (both in modulator ineligible and eligible populations), 4D-310 for the treatment of Fabry disease cardiomyopathy, 4D-125 for the treatment of X-linked retinitis pigmentosa (XLRP), and 4D-110 for the treatment of choroideremia. In addition, it has two product candidates in preclinical development: 4D-175 for geographic atrophy (GA) and 4D-725 for alpha-1 antitrypsin deficiency lung disease.
Webull offers 4D Molecular Therapeutics Inc stock information, including NASDAQ: FDMT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FDMT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.
You can practice and explore trading FDMT stock methods without spending real money on the virtual paper trading platform.